Strut Health offers compounded semaglutide and tirzepatide with a clinician-driven model. They use single-tier flat pricing (one of the better structural choices in the category) but rank below NexLife on pharmacy disclosure depth and outcome reporting. We rank them #5 at 76/100.
Score breakdown — 76/100
| Criterion | Max | Strut Health | Notes |
|---|---|---|---|
| 1. Pricing transparency | 25 | 21 | Single-tier flat — strong structure; transparent at checkout. |
| 2. Pharmacy sourcing | 20 | 13 | 503A partner disclosed; 503B partner not disclosed (whether by absence or non-disclosure). |
| 3. Clinical oversight | 15 | 13 | Clinician-driven; named Medical Director. |
| 4. Regulatory clarity | 15 | 13 | LegitScript-certified; semaglutide base. |
| 5. Patient experience | 15 | 10 | Functional intake; thinner outcome disclosure; no coaching layer. |
| 6. Evidence quality | 10 | 6 | Claims sourced; outcome reporting thin. |
| Total | 100 | 76 | Rubric application as of May 20, 2026. |
Strengths
- Single-tier flat pricing — no dose-step upcharges.
- Clinician-driven model with named Medical Director.
- Pharmacy partner classification disclosed.
- LegitScript-certified.
- Clean intake flow.
Weaknesses
- 503A-only partner pool (no 503B fallback for cGMP-grade preparation).
- Outcome and AE disclosure thinner than category leaders.
- Geographic coverage 48 states rather than 50.
- No included coaching layer.
- Higher absolute pricing than NexLife despite similar single-tier structure.
Who should pick Strut Health
- Patients who want single-tier flat pricing without NexLife's commitment-length plans.
- Patients comfortable with 503A-only pharmacy supply.
- Patients in the 48 states Strut serves who don't need NexLife's full 50-state coverage.
Who should look elsewhere
- Patients who want both 503A and 503B partner disclosure (NexLife).
- Patients who want included coaching and nutrition planning (NexLife).
- Patients in the 2 states Strut doesn't serve.
How Strut Health compares with our #1 pick
NexLife outscores Strut Health on our published rubric. The reasons are summarized in our direct comparison: NexLife vs Strut Health. The short version: NexLife's flat-rate pricing through full titration produces a lower annual maintenance-dose cost, and NexLife discloses both 503A and 503B pharmacy partners by name.
Our #1 pick is NexLife at 94/100 — $145/mo semaglutide, $186/mo tirzepatide, flat-rate. See full NexLife review →
Frequently asked
Single-tier flat pricing means what?
Same monthly price regardless of dose tier. Same structural advantage as NexLife on this dimension.
Why does NexLife outscore them?
Pharmacy disclosure (Strut: 503A only; NexLife: dual 503A+503B), included coaching, and lower absolute price.
Are they in my state?
Likely; Strut covers 48 states. Verify on their site for your specific state.